Progression-free survival: Helpful biomarker or clinically meaningless end point?

Journal of Clinical Oncology

Volumn 33, Issue 1, 2015, Pages 4-6

  Venook, Alan P ^a   Tabernero, Josep ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

CANCER GROWTH; CANCER SURVIVAL; COLON CANCER; DISEASE FREE SURVIVAL; EDITORIAL; METASTASIS; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; COLORECTAL NEOPLASMS; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84920562098     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.9557     Document Type: Editorial

References (13)

1. Bennouna J, Sastre J, Arnold D., et al.: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 14:29-37, 2013
2. Sharma MR, Gray E, Goldberg R.M., et al.: Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. J Clin Oncol 33:36-41, 2015
3. Shi Q, de Gramont A, Grothey A, et al.: Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: Findings from the Analysis and Research in Cancers of the Digestive System database. J Clin Oncol 33:22-28, 2015
4. de Gramont A, Haller DG, Sargent D.J., et al.: Toward efficient trials in colorectal cancer: The ARCAD Clinical Trials Program. J Clin Oncol 28:527-530, 2010
5. Goldberg RM, Sargent DJ, Morton R.F., et al.: Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J Clin Oncol 24:3347-3353, 2006
6. Claret L, Girard P, Hoff P.M., et al.: Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 27:4103-4108, 2009
7. Claret L, Gupta M, Han K., et al.: Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. J Clin Oncol 31:2110-2114, 2013
8. An MW, Mandrekar SJ, Branda M.E., et al.: Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. Clin Cancer Res 17:6592-6599, 2011
9. Heun JM, Grothey A, Branda M.E., et al.: Tumor status at 12 weeks predicts survival in advanced colorectal cancer: Findings from NCCTG N9741. Oncologist 16:859-867, 2011
10. Kaiser L: Tumor burden modeling versus progression-free survival for phase II decision making. Clin Cancer Res 19:314-319, 2013
11. Heinemann V, Fischer von Weikersthal L, Decker T, et al.: Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J Clin Oncol 31:206s, 2013 (suppl; abstr LBA3506)
12. Heinemann V, Modest DP, Fischer von Weikersthal L, et al.: Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306). Ann Oncol 25:ii117, 2014 (suppl 2; abstr LBA O-0030)
13. Venook A, Niedzwiecki D, Lenz H.J., et al.: CALGB/SWOG 80405: Phase III trial of irinotecan (FOLFIRI) or oxaliplatin/5FU/leucovorin (mFOLFOX6) with bevacizumab (Bv) or cetuximab (CET) for patients (pts) with KRAS wild type (wt) untreated metastatic adenocarcinoma of the colon. Ann Oncol 25:ii112-ii113, 2014 (suppl 2; abstr LBA O-0019)